Article
Endocrinology & Metabolism
Christophe E. M. De Block, Jolijn Van Cauwenberghe, Niels Bochanen, Eveline Dirinck
Summary: Over the past 100 years since the discovery of insulin, insulin preparations have significantly improved, from animal insulins to human insulins to insulin analogues. The advent of ultra-rapid-acting insulin analogues has provided a new possibility for achieving strict glucose control while maintaining convenience in insulin therapy.
DIABETES OBESITY & METABOLISM
(2022)
Review
Medicine, General & Internal
Bianca Hemmingsen, Maria-Inti Metzendorf, Bernd Richter
Summary: The study compared different long-acting insulins for the treatment of type 1 diabetes patients and found that there were no significant advantages or disadvantages among different long-acting insulins in most main outcomes. However, different insulins had varying effects on the prevention of severe hypoglycemia. More patient-important outcome data support is needed.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS
(2021)
Review
Health Care Sciences & Services
Andrea C. Tricco, Huda M. Ashoor, Jesmin Antony, Zachary Bouck, Myanca Rodrigues, Ba' Pham, Paul A. Khan, Vera Nincic, Nazia Darvesh, Fatemeh Yazdi, Marco Ghassemi, John D. Ivory, Areti Angeliki Veroniki, Catherine H. Yu, Lorenzo Moja, Sharon E. Straus
Summary: This study evaluated the efficacy and safety of different types of insulin products and biosimilar insulin in patients with T1DM. Results showed that ultra-long-acting and long-acting insulin were more effective than intermediate-acting insulin, and there were differences in fasting blood glucose and weight change among different types of insulin.
JOURNAL OF GENERAL INTERNAL MEDICINE
(2021)
Review
Endocrinology & Metabolism
Paschalis Karakasis, Dimitrios Patoulias, Konstantinos Pamporis, Djordje S. Popovic, Panagiotis Stachteas, Konstantinos I. Bougioukas, Nikolaos Fragakis, Manfredi Rizzo
Summary: This study summarizes the evidence from recently published randomized controlled trials (RCTs) on the efficacy and safety of newly developed once-weekly basal insulin analogues in terms of glycaemic control. The results suggest that once-weekly insulins are more effective in reducing HbA1c and achieving a greater time in range compared to once-daily insulin analogues. The study concludes that once-weekly basal insulin analogues are at least equally effective and safe in glycaemic management as once-daily injections in people with type 2 diabetes mellitus (T2DM).
DIABETES OBESITY & METABOLISM
(2023)
Article
Endocrinology & Metabolism
Melissa H. Lee, Barbora Paldus, Sara Vogrin, Dale Morrison, Dessi P. Zaharieva, Jean Lu, Hannah M. Jones, Emma Netzer, Lesley Robinson, Benyamin Grosman, Anirban Roy, Natalie Kurtz, Glenn M. Ward, Richard J. MacIsaac, Alicia J. Jenkins, David N. O'Neal
Summary: The study evaluated glucose control using fast-acting insulin aspart compared with insulin aspart in adults with type 1 diabetes. Faster aspart demonstrated greater overall time in range and higher postprandial glucose time in range, with no severe hypoglycemia or ketoacidosis observed.
Review
Endocrinology & Metabolism
Geremia B. Bolli, Francesca Porcellati, Paola Lucidi, Carmine G. Fanelli, David R. Owens
Summary: Insulin development in the human body has gone through extraction from animal pancreas, purification, and the emergence of regular human insulin synthesized using rDNA technology in the '80s, leading to the development of designer insulins. The introduction of rapid-acting insulin analogs has significantly improved treatment convenience for patients and reduced the risk of late hypoglycemia.
METABOLISM-CLINICAL AND EXPERIMENTAL
(2022)
Article
Medicine, General & Internal
Harpreet S. Bajaj, Jens Aberle, Melanie Davies, Anders Meller Donatsky, Marie Frederiksen, Dilek G. Yavuz, Amoolya Gowda, Ildiko Lingvay, Bruce Bode
Summary: This study compared the effectiveness and safety of icodec titrated with a dosing guide app to once-daily basal insulin analogues in treating patients with type 2 diabetes. The results showed that icodec with app was more effective in reducing HbA1c levels, improving treatment satisfaction and compliance, with similar rates of hypoglycemia compared to OD analogues.
ANNALS OF INTERNAL MEDICINE
(2023)
Article
Endocrinology & Metabolism
Rory J. McCrimmon, Alice Y. Y. Cheng, Gagik Galstyan, Khier Djaballah, Xuan Li, Mathieu Coudert, Juan P. Frias
Summary: This study compared the clinical effectiveness of iGlarLixi and BI + RAI regimens in patients with type 2 diabetes. The results showed that in real-world clinical practice, the two regimens had similar glycemic control, but iGlarLixi led to less weight gain.
DIABETES OBESITY & METABOLISM
(2023)
Review
Economics
Hailey Saunders, Ba' Pham, Desmond Loong, Sujata Mishra, Huda M. Ashoor, Jesmin Antony, Nazia Darvesh, Silkan K. Bains, Margaret Jamieson, Donna Plett, Srushhti Trivedi, Catherine H. Yu, Sharon E. Straus, Andrea C. Tricco, Wanrudee Isaranuwatchai
Summary: This study conducted a systematic review on the cost-effectiveness of insulin formulations and found that ultralong-acting insulin was cost-effective compared to other long-acting insulins, and long-acting insulin was cost-effective compared to intermediate-acting insulin.
Article
Endocrinology & Metabolism
Jason E. Black, Stewart B. Harris, Bridget L. Ryan, Guangyong Zou, Alexandria Ratzki-Leewing
Summary: Using survey data, this study found that second-generation basal insulin analogues can reduce the rates of hypoglycemia events, especially nocturnal non-severe and severe events. Clinicians should prioritize prescribing these agents for patients with type 1 and type 2 diabetes.
Article
Endocrinology & Metabolism
Philip Levin, Byron J. Hoogwerf, Janet Snell-Bergeon, Tim Vigers, Laura Pyle, Lee Bromberger
Summary: The study showed that treatment with inhaled insulin using a simple algorithm improved glycemic control in patients with diabetes, as demonstrated by reductions in both HbA1c levels and time spent within the target blood glucose range, with low rates of hypoglycemia.
ENDOCRINE PRACTICE
(2021)
Article
Endocrinology & Metabolism
Stephanie Larose, Christopher Filliter, Robert W. Platt, Oriana H. Y. Yu, Kristian B. Filion
Summary: To investigate the association between the use of long-acting insulin analogues and the increased risk of incident diabetic retinopathy (DR) in patients with type 2 diabetes, a retrospective, population-based cohort study was conducted. The results showed that there was no association between long-acting insulin analogues and the risk of incident DR compared to NPH insulin. This finding provides important reassurance regarding the safety of long-acting insulin analogues with respect to incident DR.
DIABETES OBESITY & METABOLISM
(2023)
Review
Endocrinology & Metabolism
Athina Stamati, Thomas Karagiannis, Apostolos Tsapas, Athanasios Christoforidis
Summary: This study assessed the efficacy and safety of ultra-rapid insulin analogues used with continuous subcutaneous insulin infusion systems in adults with type 1 diabetes. The results showed that ultra-rapid insulins provided better control of postprandial glucose and reduced time spent in hypoglycemia compared to rapid-acting insulin analogues. However, the use of ultra-rapid insulins may result in more unplanned infusion set changes.
DIABETES RESEARCH AND CLINICAL PRACTICE
(2022)
Article
Endocrinology & Metabolism
Ronnie Aronson, Torben Biester, Jennifer Leohr, Robyn Pollom, Helle Linnebjerg, Elizabeth Smith LaBell, Qianyi Zhang, David E. Coutant, Thomas Danne
Summary: This study compared the pharmacokinetics, glucodynamics and tolerability of ultra rapid lispro (URLi) and Humalog in children, adolescents and adults with type 1 diabetes mellitus. The results showed that URLi achieved faster onset of action, reduced early t(max), increased exposure in the first 15 minutes, and decreased exposure after 3 hours compared with Humalog. URLi also resulted in greater reduction of postprandial glucose levels at 1 hour.
DIABETES OBESITY & METABOLISM
(2023)
Review
Pharmacology & Pharmacy
Zhi-Yuan Dong, Ji-Hua Feng, Jian-Feng Zhang
Summary: This study compared the efficacy and tolerability of insulin degludec with other long-acting insulin analogues in patients with type 1 or type 2 diabetes. The results showed that insulin degludec had a greater reduction in fasting plasma glucose and a lower prevalence of hypoglycemia compared to other insulins.
CLINICAL THERAPEUTICS
(2022)
Article
Cardiac & Cardiovascular Systems
Pieter Martens, Chantal Mathieu, Thomas Vanassche
Summary: The presence of type 2 diabetes puts patients at a higher risk for cardiovascular disease, heart failure, and chronic kidney disease. Glucose control alone is not enough to prevent these complications, but new drugs like SGLT2-I and GLP-1RA show promise in reducing these risks. However, the uptake of these drugs in clinical practice, especially GLP-1RA, is low.
Review
Endocrinology & Metabolism
Athena Philis-Tsimikas, Harpreet S. Bajaj, Kamilla Begtrup, Roman Cailleteau, Amoolya Gowda, Ildiko Lingvay, Chantal Mathieu, David Russell-Jones, Julio Rosenstock
Summary: This article describes the clinical development program ONWARDS phase 3a, which investigates the use of once-weekly basal insulin icodec in the treatment of type 2 and type 1 diabetes. Six trials are being conducted to evaluate the efficacy and safety of icodec, with consideration of different clinical scenarios and comparator treatments.
DIABETES OBESITY & METABOLISM
(2023)
Article
Endocrinology & Metabolism
Caro Minschart, Astrid Lammertyn, Paul Van Crombrugge, Carolien Moyson, Johan Verhaeghe, Sofie Vandeginste, Hilde Verlaenen, Chris Vercammen, Toon Maes, Els Dufraimont, Nele Roggen, Christophe De Block, Yves Jacquemyn, Farah Mekahli, Katrien De Clippel, Annick Van Den Bruel, Anne Loccufier, Annouschka Laenen, Roland Devlieger, Chantal Mathieu, Katrien Benhalima
Summary: The level of gestational weight gain (GWG) during pregnancy is associated with adverse pregnancy outcomes in women with gestational diabetes (GDM) compared to women with normal glucose tolerance (NGT). Low GWG below recommended levels frequently occurs in GDM women without increased risk for adverse outcomes. Excessive GWG is associated with increased risk for neonatal hypoglycemia and worse metabolic profile postpartum in GDM women, and with higher rates of instrumental delivery and larger infants in NGT women.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Article
Endocrinology & Metabolism
Sara Charleer, Christophe De Block, Nancy Bolsens, Liesbeth Van Huffel, Frank Nobels, Chantal Mathieu, Pieter Gillard
Summary: This study investigates the impact of nationwide reimbursement of intermittently scanned continuous glucose monitoring (isCGM) on adults with type 1 diabetes with impaired or normal awareness of hypoglycemia over 24 months. The results show sustained improvement in severe hypoglycemia, work absenteeism, and hypoglycemia fear after isCGM reimbursement, with increased treatment satisfaction. isCGM is a valuable tool under long-term real-world conditions regardless of hypoglycemia awareness level.
DIABETES TECHNOLOGY & THERAPEUTICS
(2023)
Letter
Endocrinology & Metabolism
Chantal Mathieu, Stefano Del Prato
Editorial Material
Endocrinology & Metabolism
Chantal Mathieu, Eleanor Kennedy, Patrick Schrauwen, Hindrik Mulder
Editorial Material
Endocrinology & Metabolism
Chantal Mathieu, Jeannette Soderberg, Stefano Del Prato, Anne-Marie Felton, Xavier Cos, Carine de Beaufort, Jean-Francois Gautier, Bastian Hauck, Angus Forbes, Robert Heine, Peter Schwarz, Bart Torbeyns
Article
Endocrinology & Metabolism
Margaretha M. Visser, Sara Charleer, Steffen Fieuws, Christophe De Block, Robert Hilbrands, Liesbeth Van Huffel, Toon Maes, Gerd Vanhaverbeke, Eveline Dirinck, Nele Myngheer, Chris Vercammen, Frank Nobels, Bart Keymeulen, Chantal Mathieu, Pieter Gillard
Summary: The ALERTT1 study compared the benefits of switching from isCGM to rtCGM in adults with type 1 diabetes. The results showed that rtCGM improved glycemic control and reduced hypoglycemia worry significantly up to 24 months.
LANCET DIABETES & ENDOCRINOLOGY
(2023)
Article
Medicine, General & Internal
Lore Raets, Kim Van Hoorenbeeck, Toon Maes, Chris Vercammen, Christophe De Block, Eveline Dirinck, Inge Van Pottelbergh, Katrien Wierckx, Annouschka Laenen, Annick Bogaerts, Chantal Mathieu, Katrien Benhalima
Summary: The Belgian Diabetes in Pregnancy follow-up study (BEDIP-FUS) aims to investigate the impact of BMI, adiposity, and glucose intolerance on the metabolic profile and future risk for T2D in women and offspring after a five-year period. The study involves recruiting 375 women-offspring pairs based on the results of glucose challenge and oral glucose tolerance tests during pregnancy. The primary outcomes measured are glucose intolerance in mothers and BMI z-score in offspring. The study is important for individualizing follow-up care for women with different degrees of hyperglycemia during pregnancy and their offspring.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Cardiac & Cardiovascular Systems
Andrea M. Yeung, Jingtong Huang, Ambarish Pandey, Ibrahim A. Hashim, David Kerr, Rodica Pop-Busui, Connie M. Rhee, Viral N. Shah, Lia Bally, Antoni Bayes-Genis, Yong Mong Bee, Richard Bergenstal, Javed Butler, G. Alexander Fleming, Gregory Gilbert, Stephen J. Greene, Mikhail N. Kosiborod, Lawrence A. Leiter, Boris Mankovsky, Thomas W. Martens, Chantal Mathieu, Viswanathan Mohan, Kershaw Patel, Anne Peters, Eun-Jung Rhee, Giuseppe M. C. Rosano, David B. Sacks, Yader Sandoval, Jane Jeffrie Seley, Oliver Schnell, Guillermo Umpierrez, Kayo Waki, Eugene E. Wright Jr, Alan H. B. Wu, David C. Klonoff
Summary: The Diabetes Technology Society assembled a panel of clinician experts to review the current evidence on biomarker screening of people with diabetes for heart failure and provide recommendations for diagnosis and management to prevent disease progression.
PROGRESS IN CARDIOVASCULAR DISEASES
(2023)
Article
Biochemistry & Molecular Biology
Deirdre K. Tobias, Jordi Merino, Abrar Ahmad, Catherine Aiken, Jamie L. Benham, Dhanasekaran Bodhini, Amy L. Clark, Kevin Colclough, Rosa Corcoy, Sara J. Cromer, Daisy Duan, Jamie L. Felton, Ellen C. Francis, Pieter Gillard, Veronique Gingras, Romy Gaillard, Eram Haider, Alice Hughes, Jennifer M. Ikle, Laura M. Jacobsen, Anna R. Kahkoska, Jarno L. T. Kettunen, Raymond J. Kreienkamp, Lee-Ling Lim, Jonna M. E. Mannisto, Robert Massey, Niamh-Maire Mclennan, Rachel G. Miller, Mario Luca Morieri, Jasper Most, Rochelle N. Naylor, Bige Ozkan, Kashyap Amratlal Patel, Scott J. Pilla, Katsiaryna Prystupa, Sridharan Raghavan, Mary R. Rooney, Martin Schoen, Zhila Semnani-Azad, Magdalena Sevilla-Gonzalez, Pernille Svalastoga, Wubet Worku Takele, Claudia Ha-ting Tam, Anne Cathrine B. Thuesen, Mustafa Tosur, Amelia S. Wallace, Caroline C. Wang, Jessie J. Wong, Jennifer M. Yamamoto, Katherine Young, Chloe Amouyal, Mette K. Andersen, Maxine P. Bonham, Mingling Chen, Feifei Cheng, Tinashe Chikowore, Sian C. Chivers, Christoffer Clemmensen, Dana Dabelea, Adem Y. Dawed, Aaron J. Deutsch, Laura T. Dickens, Linda A. DiMeglio, Monika Dudenhoffer-Pfeifer, Carmella Evans-Molina, Maria Merce Fernandez-Balsells, Hugo Fitipaldi, Stephanie L. Fitzpatrick, Stephen E. Gitelman, Mark O. Goodarzi, Jessica A. Grieger, Marta Guasch-Ferre, Nahal Habibi, Torben Hansen, Chuiguo Huang, Arianna Harris-Kawano, Heba M. Ismail, Benjamin Hoag, Randi K. Johnson, Angus G. Jones, Robert W. Koivula, Aaron Leong, Gloria K. W. Leung, Ingrid M. Libman, Kai Liu, S. Alice Long, William L. Lowe, Robert W. Morton, Ayesha A. Motala, Suna Onengut-Gumuscu, James S. Pankow, Maleesa Pathirana, Sofia Pazmino, Dianna Perez, John R. Petrie, Camille E. Powe, Alejandra Quinteros, Rashmi Jain, Debashree Ray, Mathias Ried-Larsen, Zeb Saeed, Vanessa Santhakumar, Sarah Kanbour, Sudipa Sarkar, Gabriela S. F. Monaco, Denise M. Scholtens, Elizabeth Selvin, Wayne Huey-Herng Sheu, Cate Speake, Maggie A. Stanislawski, Nele Steenackers, Andrea K. Steck, Norbert Stefan, Julie Stoy, Rachael Taylor, Sok Cin Tye, Gebresilasea Gendisha Ukke, Marzhan Urazbayeva, Bart Van der Schueren, Camille Vatier, John M. Wentworth, Wesley Hannah, Sara L. White, Gechang Yu, Yingchai Zhang, Shao J. Zhou, Jacques Beltrand, Michel Polak, Ingvild Aukrust, Elisa de Franco, Sarah E. Flanagan, Kristin A. Maloney, Andrew McGovern, Janne Molnes, Mariam Nakabuye, Pal Rasmus Njolstad, Hugo Pomares-Millan, Michele Provenzano, Cecile Saint-Martin, Cuilin Zhang, Yeyi Zhu, Sungyoung Auh, Russell de Souza, Andrea J. Fawcett, Chandra Gruber, Eskedar Getie Mekonnen, Emily Mixter, Diana Sherifali, Robert H. Eckel, John J. Nolan, Louis H. Philipson, Rebecca J. Brown, Liana K. Billings, Kristen Boyle, Tina Costacou, John M. Dennis, Jose C. Florez, Anna L. Gloyn, Maria F. Gomez, Peter A. Gottlieb, Siri Atma W. Greeley, Kurt Griffin, Andrew T. Hattersley, Irl B. Hirsch, Marie-France Hivert, Korey K. Hood, Jami L. Josefson, Soo Heon Kwak, Lori M. Laffel, Siew S. Lim, Ruth J. F. Loos, Ronald C. W. Ma, Chantal Mathieu, Nestoras Mathioudakis, James B. Meigs, Shivani Misra, Viswanathan Mohan, Rinki Murphy, Richard Oram, Katharine R. Owen, Susan E. Ozanne, Ewan R. Pearson, Wei Perng, Toni I. Pollin, Rodica Pop-Busui, Richard E. Pratley, Leanne M. Redman, Maria J. Redondo, Rebecca M. Reynolds, Robert K. Semple, Jennifer L. Sherr, Emily K. Sims, Arianne Sweeting, Tiinamaija Tuomi, Miriam S. Udler, Kimberly K. Vesco, Tina Vilsboll, Robert Wagner, Stephen S. Rich, Paul W. Franks
Summary: Precision medicine, as part of contemporary evidence-based medicine, aims to reduce errors and optimize outcomes in medical decisions and health recommendations. This second international consensus report on precision diabetes medicine summarizes the findings from a systematic evidence review and highlights opportunities for clinical implementation as well as gaps in knowledge.
Meeting Abstract
Endocrinology & Metabolism
J. Peleshok, S. H. Hsia, C. Mathieu, M. K. Thomas, H. Wang
Meeting Abstract
Endocrinology & Metabolism
S. Charleer, R. De Groote, E. Lefever, P. Donne, C. De Block, C. Mathieu, P. Gillard
Meeting Abstract
Endocrinology & Metabolism
J. De Meulemeester, M. M. Visser, B. Keymeulen, C. Vercammen, M. Strivay, G. Vanhaverbeke, C. De Block, L. Van Huffel, L. Winne, I. Lowyck, K. Spincemaille, R. Radermecker, D. Ballaux, C. Mathieu, P. Gillard
Review
Medicine, Research & Experimental
Laura M. Jacobsen, Jennifer L. Sherr, Elizabeth Considine, Angela Chen, Sarah M. Peeling, Margo Hulsmans, Sara Charleer, Marzhan Urazbayeva, Mustafa Tosur, Selma Alamarie, Maria J. Redondo, Korey K. Hood, Peter A. Gottlieb, Pieter Gillard, Jessie J. Wong, Irl B. Hirsch, Richard E. Pratley, Lori M. Laffel, Chantal Mathieu, I ADA EASD PMD
Summary: Jacobsen, Sherr et al. evaluate the utility of novel technologies in the treatment of type 1 diabetes. Their systematic review finds technologies such as continuous glucose monitoring, insulin pumps, and decision support tools improve important measures (e.g., HbA1c, time in range, quality of life) allowing precision-directed uptake of technology.
COMMUNICATIONS MEDICINE
(2023)